KT brings experience in venture capital and startup operations to her current role at AbbVie Ventures, where she is expanding the corporate venture group’s investment portfolio and presence on the US west coast. Since joining AbbVie in 2017, she has driven investments and supported therapeutics company formation and growth in the region.
Prior, KT was CEO at a clinical-stage microbiome therapeutics company, through the funding and launch of its first clinical efficacy study. She has held other executive leadership and consulting roles in a number of venture-backed life science companies. Previously, KT was a partner at the venture capital firm Mohr Davidow Ventures for six years, with a focus on early stage opportunities in life science and energy. Before this, she founded and led the hub of entrepreneurship at QB3 and the University of California San Francisco during the establishment of the Mission Bay campus. KT earned a BA in Physics from UC Berkeley, and a PhD for research conducted at UC San Diego and the Salk Institute.